SCHEMBL2903151

SCHEMBL2903151

COc1ccccc1CNc1ccc2c(CN)cccc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 14/20 0.52
CYP3A4 P08684 14/20 0.52
CYP2D6 P10635 14/20 0.52
CYP2C19 P33261 13/20 0.52
TSHR P16473 11/20 0.52
USP2 O75604 10/20 0.52
LMNA P02545 8/20 0.52
ALOX15 P16050 7/20 0.52
HSD17B10 Q99714 8/20 0.51
ATM Q13315 1/20 0.51
CYP2C9 P11712 7/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
HIF1A Q16665 1/20 0.49
CLK4 Q9HAZ1 5/20 0.48
MAPK1 P28482 4/20 0.48
ACP1 P24666 1/20 0.48
SLC2A1 P11166 1/20 0.47
ALDH1A1 P00352 4/20 0.47
TP53 P04637 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2253396 0.91 CYP1A2 (0.55) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL2908880 0.87 ACP1 (0.57) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL2250736 0.86 ATM (0.56) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL2250117 0.86 CYP1A2 (0.51) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL2901691 0.85 CYP1A2 (0.56) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL2906915 0.85 CYP1A2 (0.50) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL3951241 0.83 AURKA (0.47) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL2246938 0.83 CYP1A2 (0.53) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL2251495 0.83 POLB (0.48) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL2906948 0.83 ACP1 (0.53) CYP1A2CYP3A4CYP2D6CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825253-B2 2-aminoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2010-11-02 US disclosed
EP-2076495-B1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES HOFFMANN LA ROCHE (CH) 2010-08-18 EP disclosed
EP-2076495-A1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES F.HOFFMANN-LA ROCHE AG (CH) 2009-07-08 EP disclosed
WO-2008037626-A1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES F. HOFFMANN-LA ROCHE AG (CH) 2008-04-03 WO disclosed
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES AR, ADRA2C, RCC2 CYP1A2 27/4885CYP3A4 339/4885CYP2D6 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.